

to folic acid biological activity similar to folic acid; and vitamin B6, and wherein there are no significant amounts of other micro-nutrients.

put 83/ 17. (New) The formulation of claim 16, wherein the formulation is a pharmaceutical formulation which further comprises a pharmaceutically acceptable excipient.

18. (New) The formulation of claim 16, wherein the formulation is a nutritional formulation.

B1  
cont'd 19. (New) The formulation of claim 16, wherein the formulation is in the form of a hard gelatin capsule or a soft gelatin capsule.

20. (New) The formulation of claim 16, further comprising at least one antioxidant.

put 83/ 21. (New) The formulation of claim 16, wherein the formulation comprises at least 200 µg of the at least one homocysteine-lowering agent.

22. (New) The formulation of claim 16, wherein the formulation comprises 5 mg of vitamin B12.

23. (New) The formulation of claim 16, wherein the at least one EFA is a eicosapentaenoic acid (EPA).

24. (New) The formulation of claim 23, wherein the eicosapentaenoic acid (EPA) is the ethyl ester form or the pure tri-EPA triglyceride form.

25. (New) The formulation of claim 16, wherein the EFA is arachidonic acid.

26. (New) The formulation of claim 16, wherein the EFA is gammalinolenic acid or dihomogammalinolenic acid.

27. (New) The formulation of claim 16, wherein the EFA is docosahexaenoic acid.

28. (New) The formulation of claim 16, wherein the formulation comprises two or more EFAs.

29. (New) The formulation of claim 16, wherein the formulation comprises at least 5% of the at least one EFA.

30. (New) The formulation of claim 16, wherein the formulation comprises 15% or more of the at least one EFA.

31. (New) The formulation of claim 16, wherein the formulation comprises 30% or more of the at least one EFA.

32. (New) The formulation of claim 16, wherein the formulation comprises 50% or more of the at least one EFA.

33. (New) The formulation of claim 16, wherein the formulation comprises 90% or more of the at least one EFA.

34. (New) The formulation of claim 16, wherein the formulation comprises 95% or more of the at least one EFA.

35. (New) The formulation of claim 16, wherein vitamin B12 is the only homocysteine-lowering agent.

36. (New) The formulation of claim 35, wherein vitamin B12 is in the form of hydroxocobalamin.

37. (New) The formulation of claim 16, wherein folic acid or the related compound is the only homocysteine-lowering agent.

38. (New) The formulation of claim 16, wherein the formulation is in a form suitable for oral administration.

39. (New) The formulation of claim 16, wherein the antioxidant is selected from the group consisting of: natural, synthetic or semi-synthetic vitamin E; natural, synthetic or semi-synthetic coenzyme Q; natural, synthetic or semi-synthetic alpha-lipoic acid; and natural, synthetic or semi-synthetic vitamin C.

40. (New) A method for treating or preventing of one or more of the following conditions:

(a) a cardiovascular or cerebrovascular disorder, any form of atherosclerosis of the coronary, cerebral or peripheral blood vessels, any form of heart disease, any form of cerebrovascular disease or stroke, any form of peripheral vascular disease and any form of thrombosis;

(b) diabetes or pre-diabetes (syndrome X) and any of the macro- or microvascular complications of diabetes, cardiovascular disease, retinopathy, nephropathy or neuropathy;

(c) a psychiatric disorder, schizophrenia, a schizotypal disorder and other schizophreni form disorders, bipolar disorder (mania, or manic depression), depression of any

form, and panic or anxiety disorders, sleep disorders and social phobias;

(d) a neurological or a neurodegenerative disorder, Alzheimer's disease and other forms of dementia, Parkinson's disease, multiple sclerosis, Huntington's disease and chronic pain;

(e) a kidney disorder;

(f) an inflammatory or an immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or other tissues;

(g) an eye or hearing disorder, age-related macular degeneration, age-related deafness, or tinnitus.

(h) obesity, or

(i) cancer

in a subject comprising administering to the subject the formulation of claim 16.

41. (New) A method for treating or preventing of one or more of the following conditions:

(a) a cardiovascular or cerebrovascular disorder, any form of atherosclerosis of the coronary, cerebral or peripheral blood vessels, any form of heart disease, any form of

cerebrovascular disease or stroke, any form of peripheral vascular disease and any form of thrombosis;

(b) diabetes or pre-diabetes (syndrome X) and any of the macro- or microvascular complications of diabetes, cardiovascular disease, retinopathy, nephropathy or neuropathy;

(c) a psychiatric disorder, schizophrenia, a schizotypal disorder and other schizophreni form disorders, bipolar disorder (mania, or manic depression), depression of any form, and panic or anxiety disorders, sleep disorders and social phobias;

(d) a neurological or a neurodegenerative disorder, Alzheimer's disease and other forms of dementia, Parkinson's disease, multiple sclerosis, Huntington's disease and chronic pain;

(e) a kidney disorder;

(f) an inflammatory or an immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or other tissues;

(g) an eye or hearing disorder, age-related macular degeneration, age-related deafness, or tinnitus.

(h) obesity, or

(i) cancer

*B'cond*

in a subject comprising administering to the subject the  
formulation of claim 24.

---